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Abstract
Antibiotic resistance and the shortage of novel antimicrobials are among the biggest chal-
lenges facing society. One of the major factors contributing to resistance is the use of front-
line clinical antibiotics in veterinary practice. In order to properly manage dwindling
antibiotic resources, we must identify antimicrobials that are specifically targeted to veteri-
nary applications. Nisin is a member of the lantibiotic family of antimicrobial peptides that
exhibit potent antibacterial activity against many gram-positive bacteria, including human
and animal pathogens such as Staphylococcus, Bacillus, Listeria, and Clostridium. Al-
though not currently used in human medicine, nisin is already employed commercially as an
anti-mastitis product in the veterinary field. Recently we have used bioengineering strate-
gies to enhance the activity of nisin against several high profile targets, including multi-drug
resistant clinical pathogens such as methicillin-resistant Staphylococcus aureus (MRSA)
and vancomycin-resistant enterococci (VRE) and also against staphylococci and strepto-
cocci associated with bovine mastitis. However, newly emerging pathogens such as methi-
cillin resistant Staphylococcus pseudintermedius (MRSP) pose a significant threat in terms
of veterinary health and as a reservoir for antibiotic resistance determinants. In this study
we created a nisin derivative with enhanced antimicrobial activity against S. pseudinterme-
dius. In addition, the novel nisin derivative exhibits an enhanced ability to impair biofilm for-
mation and to reduce the density of established biofilms. The activities of this peptide
represent a significant improvement over that of the wild-type nisin peptide and merit further
investigation with a view to their use to treat S. pseudintermedius infections.
Introduction
The diminished capacity of currently available antibiotics to control pathogenic bacteria is a
major cause for concern. Against this backdrop, methicillin-resistant Staphylococcus pseudin-
termedius (MRSP) has emerged over the last decade as a critically important, opportunistic ca-
nine pathogen responsible for skin, soft tissue, and surgical site infections [1]. Although
frequently detected in dogs, MRSP has also been isolated from several other host species
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including cats, horses, donkeys and birds [2]. Worryingly, MRSP has implications for public
health as transmission between humans and their pets can occur via direct and indirect contact
and infections in humans have been described [3]. MRSP can form biofilms [4,5]; complex, ses-
sile communities of bacteria embedded in an organic polymer matrix [6]. Biofilm formation is
now recognized as an important virulence factor in several Staphylococcus spp. [7], providing
the bacteria with chemical and physical protection from the host immune response and the ef-
fects of antimicrobials [8]. In addition to methicillin resistance and biofilm formation, the ac-
quisition of other resistance genes and resistance-mediating mutations in some MRSP isolates
renders these strains resistant to the majority of antimicrobial agents utilized in veterinary
medicine [9]. MRSP isolates are typically resistant to aminoglycosides, fluoroquinolones,
macrolides, lincosamides, trimethoprim sulfamethoxazol and, in many cases, to tetracycline
and chloramphenicol [9–11]. Thus new alternatives to conventional antibiotic therapies are ur-
gently needed. One group of compounds with enormous potential for therapeutic use is the
lantibiotic class of bacteriocins (bacterially derived antimicrobial peptides) [12,13]. Lantibiotics
are gene-encoded, ribosomally-synthesized peptides that are characterised by the presence of
unusual amino acids including lanthionine and/or methyllanthionine [14–16]. The most inten-
sively studied lantibiotic is nisin (Fig. 1A). Produced by Lactococcus lactis, nisin exhibits anti-
bacterial activity against a wide range of Gram-positive bacteria, including foodborne
pathogens such as staphylococci, bacilli and clostridia. Nisin is used as a food preservative in
over 50 countries and has been approved in the EU (as additive E234) and by the US Food and
Drug Administration (FDA) [17]. In addition, both nisin A (and its natural variant nisin Z) are
effective against the Gram positive pathogens responsible for bovine mastitis and have been in-
corporated into a number of products (such as Wipe Out and Mast Out) dedicated to control-
ling or treating such infections [12,18–20]. Additionally, Bayer have recently released Preva
medicated wipes containing 25μg/ml nisin for topical use on dogs, cats, and horses with derma-
tological conditions associated with bacterial infections or general cleansing (www.
animalhealth.bayerhealthcare.com). Notably, in addition to being effective against planktonic
cells of multi-drug resistant staphylococci [21,22], nisin has also demonstrated efficacy against
biofilms [22–24]. This activity can be further enhanced by taking advantage of the fact that
nisin functions synergistically with several conventional antibiotics against biofilms of MRSA
[25].
The mode of action of nisin and several other lantibiotics has been elucidated, revealing that
membrane-bound peptidoglycan precursor lipid II acts as an initial docking molecule. In the
case of nisin, this results in both the inhibition of cell wall biosynthesis and the disruption of
the cell membrane due to pore formation [26,27]. As a consequence of these two distinct and
co-operative mechanisms, microbes have been unable to develop any significant resistance to
nisin outside of the laboratory despite its widespread use in the food industry [14]. The ribo-
somal origin of lantibiotics facilitates approaches that can alter the structure of the mature pep-
tides in a more precise fashion than is possible for classical (non-ribosomal) antimicrobials,
and consequently enables the creation of lantibiotic variants with altered biological, chemical
and physical properties. Bioengineering strategies have been rewarding with respect to the in-
troduction of mutations that have a beneficial impact on the physico-chemical properties of
nisin, including better solubility and improved stability [28,29] as well as an enhanced ability
to diffuse through complex polymers [30]. With respect to increasing antimicrobial activity,
this was initially achieved through the creation of bioengineered nisin derivatives with superior
antimicrobial activity against some non-pathogenic targets [31,32]. Notably, nisin Z N20K and
M21K (N20K denotes a change from Asn to Lysine at position 20 of the propeptide) were the
first bioengineered nisin derivatives to show enhanced activity against pathogenic bacteria,
namely Shigella, Pseudomonas and Salmonella species [29]. The first nisin derivatives with
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improved activity against Gram-positive pathogens were nisin A N20P, M21V, K22S and
K22T [33]. Nisin A M21V has since been designated as nisin V and has also been found to ex-
hibit enhanced activity against a wide range of targets, including numerous drug resistant
strains [34]. A more comprehensive bioengineering of the hinge region (residues 20–22) re-
vealed the benefits of incorporating small chiral amino acids leading to the rational design of
nisin derivatives with enhanced properties [35]. Outside of the hinge region, several nisin A de-
rivatives were described that displayed increased potency against a range of Gram-positive tar-
gets, with S29G and S29A representing the first nisin derivatives which display enhanced
activity against both Gram-positive and Gram-negative bacteria [36]. Finally, derivatives bio-
engineered at lysine 12 (K12), located in a flexible region located between rings B and C of the
peptide also displayed enhanced activity [37]. Collectively, these studies demonstrate that bio-
engineering can both improve the activity of nisin against sensitive cells as well as alter its tar-
get spectrum. In this study, we screen a bank of nisin derivatives to identify novel peptides that
exhibit enhanced potency against an MRSP target strain, S. pseudintermedius DK729. A novel
variant was identified with improved potency against strains of S. pseudintermedius in deferred
antagonism and minimum inhibitory concentration assays. Importantly, the nisin derivative
was also more effective in preventing biofilm formation, and in reducing the biofilm mass
formed on microtiter plates. To our knowledge, this is the first report of a bioengineered lanti-
biotic peptide with enhanced efficacy against this pathogen or against bacterial biofilms.
Fig 1. Structure of nisin A and deferred antagonism assays of nisin A and nisin I4V. (A) Residues are
represented in the single letter code. Post translational modifications are indicated as follows, Dha:
dehydroalanine, Dhb: dehydrobutyrine, Abu: 2-aminobutyric acid, A-A: lanthionine, Abu-A: 3-
methyllanthionine. (B) Growth inhibition of S. intermedius DSM 20373, S. pseudintermediusDK729 and S.
pseudintermedius DSM21284 by the nisin A producing strain L. lactis NZ9800 pDF05 (pCI372-nisA) and the
nisin derivative I4V producing strain L. lactis NZ9800 pDF12 (nisA-I4V).
doi:10.1371/journal.pone.0119684.g001
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Materials and Methods
Bacterial Strains and Growth Conditions
L. lactis strains were grown in M17 broth supplemented with 0.5% glucose (GM17) or GM17
agar at 30°C. E. coli was grown in Luria-Bertani broth with vigorous shaking or agar at 37°C.
Staphylococcus, Bacillus and Streptococcus strains were grown in Brain Heart Infusion (BHI) or
BHI agar at 37°C. Antibiotics were used where indicated at the following concentrations:
Chloramphenicol at 10 and 20 μg ml-1, respectively for L. lactis and E. coli.
Creation and screening a bank of nisin derivatives
Mutagenesis of the nisA gene was carried out as described previously [33]. Briefly, saturation
mutagenesis was carried out using pDF05 (pCI372-nisA) as template and using oligonucleo-
tides as listed in (Table 1) containing an NNK codon in place of each native codon. PCR ampli-
fication was performed in a 50 μl reaction containing approximately 0.5 ng of target DNA
(pDF05), 1 unit Phusion High-Fidelity DNA polymerase (Finnzymes, Finland), 1 mM dNTPs
and 500 ng each of the appropriate forward and reverse oligonucleotide. The reaction was pre-
heated at 98°C for 2 min, and then incubated for 29 cycles at 98°C for 30 s, 55°C for 15 s and
72°C for 3 min 30 s, and then finished by incubating at 72°C for 3 min 30 s. Amplified products
were treated with Dpn1 (Stratagene) for 60 min at 37°C to digest template DNA and purified
using the QIAquick PCR purification kit. Following transformation of E. coli Top 10 cells plas-
mid DNA was isolated and sequenced using primers pCI372FOR and pCI372REV (Table 1) to
verify that mutagenesis had taken place. Approximately 150 transformants were chosen at ran-
dom for each position and inoculated into 96-well plates containing GM17 chloramphenicol,
incubated overnight and stored at −20°C after addition of 80% glycerol. Deferred antagonism
assays were performed by replicating strains on GM17 agar plates and allowing them to grow
overnight before overlaying with BHI agar (0.75% w/v agar) seeded with the appropriate
indicator strain.
Mass Spectrometry
For Colony Mass Spectrometry (CMS) bacteria were collected with sterile plastic loops and
mixed with 50 μl of 70% isopropanol adjusted to pH 2 with HCl. The suspension was vortexed,
the cells spun down in a benchtop centrifuge at 14,000 r.p.m. for 2 min, and the supernatant
was removed for analysis. Mass Spectrometry in all cases was performed with an Axima CFR
plus MALDI TOF mass spectrometer (Shimadzu Biotech, Manchester, UK). A 0.5μl aliquot of
matrix solution (alpha-cyano-4-hydroxy cinnamic acid (CHCA), 10 mg ml-1 in 50% acetoni-
trile-0.1% (v/v) trifluoroacetic acid) was placed onto the target and left for 1–2 min before
being removed. The residual solution was then air dried and the sample solution (resuspended
lyophilised powder or CMS supernatant) was positioned onto the precoated sample spot. Ma-
trix solution (0.5μl) was added to the sample and allowed to air-dry. The sample was subse-
quently analysed in positive-ion reflectron mode.
Nisin purification
2 litres of Tryptone Yeast (TY) broth were incubated for 20 hours with 1% inoculum of an
overnight culture of producing strain. This culture was centrifuged for 20 minutes @ 7000rpm.
The supernatant was decanted and passed through 60 g of pre equilibrated Amberlite XAD16
beads (Sigma-Aldrich). The beads were washed with 500 ml 30% ethanol and eluted with
500 ml 70% isopropanol (IPA) (Fisher) 0.1% trifluoroacetic acid (TFA) (Sigma-Aldrich). Con-
comitantly, the cell pellets were resuspended in 300 ml of 70% IPA 0.1%TFA and stirred at
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room temperature for 3 hours followed by centrifugation. This cell supernatant was combined
with that referred to above and concentrated through rotary-evaporation (Buchi, Switzerland)
to approximately 250 ml. Following pH adjustment to 4.0 further concentration was achieved
Table 1. Oligonucleotides utilised in this study.
Primer name Sequence
NisI1degFOR 5’ ATT ACA AGT NNK TCG CTA TGT ACA CCC GGT TGT AAA ACA 3’
NisI1degREV 5’ ACA TAG CGA MNN ACT TGT AAT GCG GGT TGA TGC ACC TGA 3’
NisT2degFOR 5’ CCA CGC ATT NNK AGT ATT TCG CTA TGT ACA CCC GGT TGT 3’
NisT2degREV 5’ CGA AAT ACT MNN AAT GCG GGT TGA TGC ACC TGA ATC TTT 3’
NisI4degFOR 5’ ATT ACA AGT NNK TCG CTA TGT ACA CCC GGT TGT AAA ACA 3’
NisI4degREV 5’ ACA TAG CGA MNN ACT TGT AAT GCG TGG TGA TGC ACC TGA 3’
NisS5degFOR 5’ ACA AGT ATT NNK CTA TGT ACA CCC GGT TGT AAA ACA GGA 3’
NisS5degREV 5’ TGT ACA TAG MNN AAT ACT TGT AAT GCG TGG TGA TGC ACC 3’
NisL6degFOR 5’ AGT ATT TCG NNK TGT ACA CCC GGT TGT AAA ACA GGA GCT 3’
NisL6degREV 5’ GGG TGT ACA MNN CGA AAT ACT TGT AAT GCG TGG TGA TGC 3’
NisP9degFOR 5’ CTA TGT ACA NNK GGT TGT AAA ACA GGA GCT CTG ATG GGT 3’
NisP9degREV 5’ TTT ACA ACC MNN TGT ACA TAG CGA AAT ACT TGT AAT GCG 3’
NisG10degFOR 5’ TGT ACA CCC NNK TGT AAA ACA GGA GCT CTG ATG GGT TGT 3’
NisG10degREV 5’ TGT TTT ACA MNN GGG TGT ACA TAG CGA AAT ACT TGT AAT 3’
NisG14degFOR 5’ TGT AAA ACA NNK GCT CTG ATG GGT TGT AAC ATG AAA ACA 3’
NisG14degREV 5’ CAT CAG AGC MNN TGT TTT ACA ACC GGG TGT ACA TAG CGA 3’
NisA15degFOR 5’ AAA ACA GGA NNK CTG ATG GGT TGT AAC ATG AAA ACA GCA 3’
NisA15degREV 5’ ACC CAT CAG MNN TCC TGT TTT ACA ACC GGG TGT ACA TAG 3’
NisL16degFOR 5’ ACA GGA GCT NNK ATG GGT TGT AAC ATG AAA ACA GCA ACT 3’
NisL16degREV 5’ ACA ACC CAT MNN CGA TCC TGT TTT ACA ACC GGG TGT ACA 3’
NisM17degFOR 5’ GGA GCT CTG NNK GGT TGT AAC ATG AAA ACA GCA ACT TGT3’
NisM17degREV 5’ GTT ACA ACC MNN CAG AGC TCC TGT TTT ACA ACC GGG TGT 3’
NisG18degFOR 5’ GCT CTG ATG NNK TGT AAC ATG AAA ACA GCA ACT TGT CAT 3’
NisG18degREV 5’ CAT GTT ACA MNN CAT CAG AGC TCC TGT TTT ACA ACC GGG 3’
NisA24degFOR 5’ ATG AAA ACA NNK ACT TGT CAT TGT AGT ATT CAC GTA AGC 3’
NisA24degREV 5’ ATG ACA AGT MNN TGT TTT CAT GTT ACA ACC CAT CAG AGC 3’
NisH27degFOR 5’ GCA ACT TGT NNK TGT AGT ATT CAC GTA AGC AAA TAA TCT 3’
NisH27degREV 5’AAT ACT ACA MNN ACA AGT TGC TGT TTT CAT GTT ACA ACC 3’
NisI30degFOR 5’ CAT TGT AGT NNK CAC GTA AGC AAA TAA TCT AGA GTCG AC 3’
NisI30degREV 5’ TTT GCT TAC GTG MNN ACT ACA ATG ACA AGT TGC TGT TTT 3’
NisH31degFOR 5’ TGT AGT ATT NNK GTA AGC AAA TAA TCT AGA GTC GAC CTG 3’
NisH31degREV 5’ TTT GCT TAC MNN AAT ACT ACA ATG ACA AGT TGC TGT TTT 3’
NisV32degFOR 5’ AGT ATT CAC NNK AGC AAA TAA TCT AGA GTC GAC CTG CAG 3’
NisV32degREV 5’ TTA TTT GCT MNN GTG AAT ACT ACA ATG ACA AGT TGC TGT 3’
NisS33degFOR 5’ ATT CAC GTA NNK AAA TAA TCT AGA GTC GAC CTG CAG CAA 3’
NisS33degREV 5’AGA TTA TTT MNN TAC GTG AAT ACT ACA ATG ACA AGT TGC 3’
NisK34degFOR 5’ CAC GTA AGC NNK TAA TCT AGA GTC GAC CTG CAG CAA TGG 3’
NisK34degREV 5’ TCT AGA TTA MNN GCT TAC GTG AAT ACT ACA ATG ACA AGT 3’
pCI372FOR 5’- CGGGAAGCTAGAGTAAGTAG -3'
pCI372Rev 5’- ACCTCTCGGTTATGAGTTAG -3’
Emboldened sequences represent degenerate codons (N = A+C+G+T, K = G+T, M = A+C). Underlined sequence corresponds to plasmid (pCI372) DNA.
doi:10.1371/journal.pone.0119684.t001
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through the use of a Phenomenex SPE C-18 column to a final volume of 60 ml. 8 ml of this
sample was concentrated, through rotary evaporation, to 2 ml and purified through HPLC
using a Phenomenex C12 Reverse-Phase (RP) HPLC column (Jupiter 4 μ proteo 90 Å, 250 X
10.0 mm, 4 μm). To facilitate this, a gradient of 30–50% acetonitrile (Fisher) containing 0.1%
TFA was developed. The relevant fractions were collected and pooled, subjected to rotary-evap-
oration to remove acetonitrile and freeze-dried (LABCONCO). The purified peptides were
subjected to MALDI-ToF Mass Spectrometric analysis to confirm their purity before use.
Minimum Inhibitory Concentration assays
Minimum inhibitory concentration determinations were carried out in triplicate in 96 well
microtitre plates. 96 well microtitre plates were pre-treated with bovine serum albumin (BSA)
prior to addition of the peptides. Briefly, to each well of the microtitre plate 200 μL of phos-
phate buffered saline (PBS) containing 1% (w/v) bovine serum albumin (PBS/BSA) was added
and incubated at 37°C for 30 min. The wells were washed with 200 μL PBS and allowed to dry.
Target strains were grown overnight in the appropriate conditions and medium, subcultured
into fresh broth and allowed to grow to an OD600 of*0.5, diluted to a final concentration of
105 cfu ml−1 in a volume of 0.2 ml. The lyophilised peptides were resuspended in 0.005% acetic
acid to a stock concentration of 30 μM.Wild type nisin and nisin I4V mutant peptides were ad-
justed to a 7.5 or 5.0 μM or 500 nM starting concentration and 2-fold serial dilutions of each
peptide were made in 96 well plates for a total of 12 dilutions. The target strain was then added
and after incubation for 16 h at 30°C or 37°C the MIC was read as the lowest peptide concen-
tration causing inhibition of visible growth.
Growth curve experiments
For growth experiments, overnight cultures were transferred (107 cfu ml−1 in a volume of
1.0 ml.) into BHI supplemented with the relevant concentration of wild-type and I4V peptides,
and subsequently 0.2mls was transferred to 96 well microtitre plates (Sarstedt). Cell growth
was measured spectrophotometrically over 24-h periods by using a SpectraMax spectropho-
tometer (Molecular Devices, Sunnyvale, Calif.).
Biofilm formation
Static microtitre plate assays based on a previous study [38], but with modifications to optimize
the assay, were used to investigate the biofilm formation and nisin treatments. TSB (Merck)
broth supplemented with 1% D-(+)-glucose (Sigma Aldrich) (TSBg) was used in these assays
which aids in biofilm formation. Briefly, a 1: 100 dilution was performed by adding 2 μl of log
phase cells (107 CFUml−1 of each culture) to 198 μl of TSBg in wells of a sterile 96-well microti-
tre plate (Sarstedt, Leicester, UK), giving a starting inoculum of 105 CFU ml−1; 200 μl of TSBg
was added to a set of wells as a negative control. All wells were seeded in triplicate. Microtitre
plates were then incubated at 37°C for 48 h to allow biofilm formation to occur. Washing
(PBS) and staining of wells (0.05% crystal violet) was carried out as described previously [39].
Biofilm prevention with nisin peptides
The ability of nisin and the nisin mutant I4V to prevent biofilm formation was carried out as
described above with the following modifications. At the beginning of the assay, nisin peptides
were added to the microtitre plate wells at 1X 1/2X, 1/4X, 1/8X, 1/16X MIC in TSBg and incu-
bated at 37°C for 24 hrs. S. pseudintermedius cells alone were inoculated into a third set of wells
as untreated controls. The plates were removed and gently washed once with PBS and stained
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with 0.05% crystal violet as described previously, and optical density readings were taken at
595 nm (OD595) to determine the final biofilm biomass.
Biofilm treatment with purified nisin A and nisin derivative I4V peptides
Biofilm formation was carried out as described earlier. After biofilms were established and
washed once with phosphate buffered saline (PBS), nisin peptides were added to the microtitre
plate wells at 1X, 2X, 4X, 8X and 16X the relevant MIC as previously determined. All wells
were seeded in triplicate. Following incubation for 24 h, at 37°C, the plates were removed and
gently washed once with PBS and stained with 0.05% crystal violet as described previously, and
optical density readings were taken at 595 nm (OD595) to determine the final biofilm biomass.
Alternatively, following incubation for 24 h, at 37°C, the biofilms exposed to peptides at 16X
MIC were gently washed once with PBS then 100 μL of a solution containing 500 mg XTT/L
(2,3-bis[2-methyloxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide) (Sigma) and
10mMmenadione (Sigma) was added to each well. Microtitre plates were incubated for 2 h at
37°C in the dark. Absorbance was measured at 490nm using a microtiter plate reader (Molecu-
lar Devices Spectramax M3, Sunnyvale CA, USA). Data obtained in triplicate were calculated
and expressed as the mean ± standard deviations.
Results
Identification of nisin derivatives with enhanced bioactivity against S.
pseudintermedius and S. intermedius
A site-saturation mutagenesis-based strategy was used to generate a bank of strains producing
bioengineered nisin derivatives in which 19 residues (I1, T2, I4, S5, L6, P9, G10, G14, A15, L16,
M17, G18, A24, H27, I30, H31, V32, S33 and K34) were each randomised to potentially all
other natural amino acids. These 19 residues include all those not involved in lanthionine ring
formation, and those which had previously been the focus of bioengineering based investiga-
tions in our laboratory (K12, N20, M21, K22 and S29). The resultant bank of approximately
3,000 individual producers was screened using deferred antagonism agar diffusion assays to
identify those with display enhanced bioactivity (which reflects a combination of production
and specific activity). Candidates were distinguished by zones of clearing that were greater
than those generated by the nisin A producing control against the target S. pseudintermedius
DK729. From this screen 47 potentially enhanced producers were selected for further investiga-
tion. Mass spectrometric analysis of the peptide produced by each strain established that these
corresponded to 10 unique mutants (data not shown). However, the variant with an isoleucine
to valine substitution located within ring A at position 4 (I4V) consistently exhibited improved
bioactivity in deferred antagonism assays against the S. pseudintermedius (DK729, DSM21284)
and S. intermedius (DSM20373) strains utilized in this study (Fig. 1B; Table 2). On this basis,
the nisin I4V derivative was selected for purification and specific activity assays. The nine other
enhanced derivatives will be the subject of future investigations.
MIC-based investigations demonstrate enhanced specific activity of
nisin I4V
Although deferred antagonism agar diffusion assays can rapidly assess the bioactivity of a pro-
ducer strain, differences in zone size can result from altered diffusion rates in agar, or from in-
creased levels of production, or from changes in specific activity. To confirm that the enhanced
activity of variant I4V was due to increased specific activity, the activity of the purified peptide
was assessed using classical broth-based minimum inhibitory concentration (MIC)
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determination assays. Following high performance liquid chromatography (HPLC) and freeze-
drying to obtain purified peptide, MIC assays were carried out using equimolar concentrations
of nisin A and nisin A I4V against a range of Gram positive targets including S. pseudinterme-
dius DK729, S. pseudintermedius DSM21284, S. intermedius DSM20373, S. aureus DPC5243, S.
aureus RF122, S. uberis ATCC, B. cereus DPC6087 and Lactococcus lactis spp. lactisHP. The
MIC was determined to be the lowest concentration of peptide that resulted in the absence of
visible growth of the target strain after 16 hours at 37°C. This method established an MIC of
3.0 mg/L for nisin A against S. intermedius DSM20373 (Table 3). This is within the MIC range
described in a previous study carried out with nisin (MIC90 of 3.2 mg/L) against a selection of
methicillin resistant staphylococci (S. aureus, S. intermedius and S. schleiferi) [40]. In contrast,
the MIC of nisin A I4V was determined to be 1.5 mg/L (0.468 μM), a two-fold increase in spe-
cific activity. MIC determinations established that the MIC of nisin A for S. pseudintermedius
DK729 and S. pseudintermedius DSM21284 was 2 and 1 mg/L (0.625 and 0.313μM), respective-
ly. In contrast, the MIC of nisin I4V was determined to be 1 and 0.25 mg/L (0.313 and 0.075
μM) against the same targets, reflecting a 2 and 4 fold increase in specific activity (Table 3). To
determine if the enhanced activity of I4V relative to nisin A is target specific MICs were as-
sessed against a number of other targets. S. aureus DPC5243 and S. aureus RF122 were chosen,
both of which were originally associated with bovine mastitis [41,42]. Against DPC5243, the
I4V derivative again displayed a two-fold decrease in potency as evident by MIC values of 1.50
Table 2. Deferred antagonism assays of L. lactis NZ9800 strains producing nisin A (wild type
control) and the nisin derivative I4V against representative strains of S. pseudintermedius and S.
intermedius.
Strain Nisin A Nisin I4V P-value
mm mm
S. pseudintermedius DK729 16.90 ± 0.48 17.96 ± 0.50 0.009
S. pseudintermedius DSM21284 16.88 ± 0.29 18.06 ± 0.14 0.008
S. intermedius DSM 20373 16.84 ± 0.27 18.27 ± 0.07 0.039
Values are the mean of triplicate deferred antagonism assays and represent zone of inhibition (diameter of
zone). All values in bold reached statistical signiﬁcance compared to nisin control (Student’s t-test: P <
0.05).
doi:10.1371/journal.pone.0119684.t002
Table 3. Speciﬁc activity of nisin A and nisin I4V against a range of indicator organisms.
Strain Nisin A Nisin I4V Fold difference
mg/L (μM) mg/L (μM)
S. pseudintermedius DK729 2 (0.625) 1 (0.313) 2
S. pseudintermedius DSM21284 1 (0.313) 0.25 (0.075) 4
S. intermedius DSM 20373 3.0 (0.936) 1.5 (0.468) 2
S. aureus DPC 5243 0.75 (0.234) 1.50 (0.468) -2
S. aureus RF122 1.5 (0.468) 1.5 (0.468) 0
L. lactis spp lactis HP 0.2 (0.062) 0.2 (0.062) 0
S. uberis ATCC 25 (7.5) 12.57 (3.75) 2
B. cereus DPC 6087 6.28 (1.875) 6.28 (1.875) 0
Results from minimum inhibitory concentration assays of puriﬁed nisin A and nisin I4V against various Gram-positive targets. Values given are identical
results from three independent determinations. Fold Difference represents the improvement of I4V compared to nisin against the relevant indicator.
doi:10.1371/journal.pone.0119684.t003
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mg/L and 0.75 mg/L (0.468μM and 0.234μM), respectively. However, no difference in specific
activity was observed against S. aureus RF122, with an MIC value of 1.5 mg/L (0.468 μM) for
both parent and variant nisin. The I4V derivative displayed enhanced efficacy (12.57 mg/L) rel-
ative to nisin A (25 mg/L) against the strain S. uberis ATCC 700407 (also associated with bo-
vine-mastitis). However, no difference in MIC was observed in experiments with B. cereus
DPC 6087 (6.28 mg/L) or L. lactis spp. lactisHP (0.2 mg/L). This variation in target specificity
has previously been observed in the case of other nisin derivatives such as N20P, which dis-
played a two-fold increase in specific activity against S. aureus ST528 (MRSA) but was 75% less
active against Streptococcus agalactiae ATCC13813 [33].
Growth curve-based comparisons of the activity of nisin A and nisin I4V
Having established the enhanced specific activity of nisin I4V against the representative S.
pseudintermedius and S. intermedius strains through end-point MIC assays, further analysis
was carried out by means of growth curves in a bid to reveal more subtle details of the impact
of nisin and nisin I4V peptides on bacterial viability. In each instance the results were consis-
tent with the enhanced potency of I4V as revealed by MIC assays. For S. pseudintermedius
DSM 21284 (1 X 107 cfu/ml), nisin A caused a slight delay in growth relative to the non nisin-
containing control at the concentration of peptide employed (0.26 mg/L) (Fig. 2A). Identical
concentrations of nisin I4V resulted in a greatly extended lag time, highlighting its greater po-
tency. Similar results were observed for S. pseudintermedius DK729 (Fig. 2B) and S. interme-
dius DSM 20373 (Fig. 2C), in that a sub-lethal concentration (0.52 mg/L) of the nisin A peptide
brought about a slight delay in growth when compared to the non-peptide containing control,
whereas the I4V peptide at the equivalent concentration extended the lag phase of growth by
several hours.
Investigation of the anti-biofilm activity of Nisin A and nisin I4V
Biofilm formation is now recognised as an important virulence factor among Staphylococcus
species [7]. The ability to form a biofilm is only recently gaining attention in the case of S. pseu-
dintermedius [4]. Indeed, in a study involving 140 S. pseudintermedius strains isolated from
dogs, 96% were classified as strong or moderate biofilm producers [4]. The microtiter-plate test
is one of the most frequently used techniques for quantifying biofilm formation [43,44]. Prior
to initiating studies with nisin peptides, we evaluated the biofilm forming abilities of S. pseudin-
termedius DK729, S. pseudintermedius DSM21284 and S. intermedius DSM20373. All three
strains formed biofilms (when grown in TSB supplemented with 1.0% glucose; TSBg) as deter-
mined using 96 well flat-bottomed polystyrene plates and analysed by crystal violet staining
Fig 2. Growth curve analysis of strains in nisin A and nisin I4V peptides. (A) S. pseudintermedius
DSM21284 in 0.26 mg/L of nisin A (closed square), I4V (closed diamond) and no peptide (open circle), and
(B) S. pseudintermedius DK729 in 0.52 mg/L of Nisin A (closed square), I4V (closed diamond) and no peptide
(open circle) and (C) S. intermedius DSM20373 in 0.52 mg/L of Nisin A (closed square), I4V (closed
diamond) and no peptide (open circle).
doi:10.1371/journal.pone.0119684.g002
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(data not shown). We employed the same methodology to study the ability of nisin A and nisin
derivative I4V peptides to inhibit biofilm formation in the case of S. pseudintermedius DK729
as a representative strain and to observe the effect of increasing concentrations of nisin pep-
tides on pre-formed biofilms of S. pseudintermedius DK729 and S. pseudintermedius
DSM21284. For biofilm prevention studies, the MIC of nisin A against S. pseudintermedius
DK729 was calculated to be at 0.625 μM (1X concentration). This concentration and several di-
lutions were added to the microtitre plate wells containing TSBg and the target strain before in-
cubation at 37°C for 24 hrs. Following staining and optical density readings at 595 nm
(OD595), a significant reduction in S. pseudintermedius DK729 biofilm mass was observed in
wells containing 1X MIC of nisin I4V compared to those treated with 1X nisin A (Fig. 3A).
When lower concentrations (1/2X, 1/4X, 1/8X and 1/16X) of the peptides were used, a similar
biofilm density was observed for cells in the presence of nisin A, nisin I4V and the untreated
control. Further analysis by way of growth curves was carried out at 0.625 μM (1X concentra-
tion) that revealed a greater inhibition on growth of S. pseudintermedius DK729 (Fig. 3B), indi-
cating that at the concentration used the nisin I4V derivative is more effective in preventing
biofilm formation than nisin A due to enhanced growth inhibition.
Next, biofilms of S. pseudintermedius DK729 and S. pseudintermedius DSM21284 pre-
formed on a 96-well plate were incubated with the peptides at a concentration of 1X, 2X 4X, 8X
and 16X MIC for 24 hours. Subsequently, the biofilm mass was determined by crystal violet
staining and optical density readings at 595 nm. In the case of S. pseudintermedius DK729, a
statistically significant reduction (p< 0.01) in biofilm mass was observed at 4X, 8X and 16X
MIC (1.25, 2.5 and 5 μM, respectively) of I4V treated biofilms compared to untreated control
biofilms or biofilms treated with the corresponding concentration of nisin A (Fig. 4A). Similar-
ly, a reduction in biomass was observed for S. pseudintermedius DSM21284 biofilms treated
with 8X (p< 0.001) and 16X (p< 0.01) MIC of I4V peptide (equivalent to 2 and 4 mg/L, re-
spectively) compared to the wild-type nisin A treated biofilms (Fig. 4B).
Further analysis was carried out to examine the effect on cell viability of the biofilms follow-
ing nisin treatment using a rapid colorimetric assay (XTT). The results reveal that following
treatment of S. pseudintermedius DK729 with 16X MIC nisin A and nisin I4V, viable cells are
still present in the biofilm in each case (Fig. 5). The lower absorbance values observed for nisin
Fig 3. Inhibition of biofilm formation with nisin A and nisin I4V peptides. (A) Results of treatment of S.
pseudintermedius DK729 with 1, 1/2, 1/4, 1/8 and 1/16XMIC of nisin A and nisin I4V peptides for 24 hrs prior
to biofilm formation. The amount of biofilm was quantified by measuring the OD595 of crystal violet dissolved
in acetic acid. The means and standard deviations of triplicate determinations are presented. Asterisks
indicate statistically significant differences (Student’s t-test) between peptides used at similar concentration
(** = p< 0.01) and (B) Growth curve analysis of strain S. pseudintermediusDK729 in 1X MIC peptides of
nisin A (closed square), I4V (closed diamond) and no peptide (open circle).
doi:10.1371/journal.pone.0119684.g003
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I4V compared to that for nisin A is likely due to the reduction in biofilm density following pep-
tide treatment (in agreement with previous crystal violet assays (Fig. 6). However, these find-
ings are significant in that the XTT assay provides evidence relating to the viability of the
remaining biofilm cells following peptide treatment which cannot be established via crystal
violet staining.
Fig 4. Treatment of biofilms with nisin A and nisin I4V peptides. (A) S. pseudintermedius DK729 and (B)
S. pseudintermedius DSM 21284 with 1, 2, 4, 8 and 16XMIC of nisin A and nisin I4V peptides for 24 hrs as
evaluated by crystal violet (CV) staining. The amount of biofilm was quantified by measuring the OD595 of CV
dissolved in acetic acid. The means and standard deviations of triplicate determinations are presented.
Asterisks indicate statistically significant differences (Student’s t-test) between peptides used at similar
concentration (* = p< 0.05, ** = p< 0.01, *** = p< 0.001).
doi:10.1371/journal.pone.0119684.g004
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Discussion
S. pseudintermedius has emerged as a major challenge for veterinary practitioners owing to its
extensive multi-drug resistance and its characteristics as a nosocomial pathogen. Moreover, its
ability to form biofilms, complex structures that confer increased resistance to chemotherapies
and host defense mechanisms, serves only to compound the problem. As the emergence of
MRSP is most likely linked to selective pressure from antimicrobials, more stringent limitations
on their use in companion animals may become a reality. Indeed, the prospective use in ani-
mals of antimicrobials licensed in human medicine, such as vancomycin, mupirocin and rifam-
picin is controversial, due to the risk for development of resistance against these agents [45].
Consequently, research into the most advantageous treatment strategies for existing antimicro-
bial agents as well as alternatives to conventional therapy is urgently required. Due to their
many unique properties, the lantibiotic class of bacteriocins would seem to have the potential
to breach the gap between effective antibiosis and increasingly drug-resistant clinical and veter-
inary microbes. Because lantibiotics are produced as gene-encoded pre-peptides, they are
much more amenable than classical antibiotics to bioengineering which could lead to the gen-
eration of a new arsenal of potent antimicrobials. The identification of bioengineered lantibio-
tic derivatives with improved activity is becoming a more frequent event as a result of the
creation of larger banks of engineered peptides [33,46,47]. Here, we employed a PCR-based
bioengineering strategy to create approximately 3,000 nisin derivatives encompassing 19
amino acid positions of nisin not previously targeted by our laboratory with the aim of identi-
fying derivatives with enhanced potency against S. pseudintermedius. Although studies relating
to the effectiveness of nisin against strains of S. pseudintermedius have not been published to
Fig 5. Colorimetric readings of biofilms. Viability of S. pseudintermedius DK729 following treatment with
16X MIC of nisin A and nisin I4V peptides and untreated control for 24 hrs as evaluated by the XTT (2,3-bis[2-
methyloxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide) assay measured using a microtiter plate
reader. Asterisks indicate statistically significant differences (Student’s t-test) between peptides used at
similar concentration (* = p< 0.05).
doi:10.1371/journal.pone.0119684.g005
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date, previous investigations have been carried out on the antimicrobial efficacy of nisin against
methicillin resistant strains of staphylococci (N = 100) isolated from companion animals (S.
aureus, S. intermedius and S. schleiferi) (40). The values obtained are in close agreement with
the MIC values of nisin A against S. pseudintermedius and S. intermedius strains as determined
in this study (1–3 mg/L). The fact that the activity of nisin I4V against these strains is enhanced
is notable given their capacity to become multi-drug resistant. Indeed, antibiotic susceptibility
tests carried out against S. pseudintermedius DK729 and DSM21284 and S. intermedius
DSM20373 indicated that these strains are resistant to a variety of antibiotics, including ampi-
cillin, streptomycin, erythromycin and clindamycin (data not shown). The enhanced efficacy
of nisin I4V against these targets reveals that the mechanisms via which these pathogens have
developed resistance to antibiotics do not negate the beneficial consequences of the I4V change.
The fact that nisin I4V prevents biofilm formation more successfully than parental nisin A,
and indeed is also more effective at reducing the density of established biofilms, is a significant
finding. Critically, several studies have shown that nisin can penetrate even the deepest part of
a biofilm matrix [22,48]. Davison and co-workers demonstrated that nisin caused a rapid and
uniform loss of green fluorescence from all parts of a Staphylococcus epidermidis biofilm [48].
Indeed, nisin (MW, 3354) accessed the interior of biofilm cell clusters faster than the other
smaller compounds under examination, including a quaternary ammonium compound (MW,
357) and chlorine (MW, 50). The authors proposed that the biofilm penetration time of nisin
implies that this agent is not neutralized or bound by the cells or matrix of the biofilm and no-
tably, no evidence of a nisin-tolerant subpopulation was seen [48]. Nisin A has also been
shown to be effective against biofilms of several strains of S. aureus (including MRSA) and S.
epidermidis [22]. However, despite showing the effectiveness of nisin to kill biofilm-associated
cells, none of these studies reported any significant reduction in biofilm density at the concen-
tration of nisin used. It is thus significant that the nisin I4V peptide exhibits superior activity in
reducing biofilm density compared to nisin A and is the first such report for a bioengineered
peptide. Future mode of action studies will concentrate on determining the basis of this
novel finding.
Fig 6. Morphology of nisin-treated biofilms examined by microscopy. (A) Examination of S.
pseudintermedius DK729 and (B) S. pseudintermedius DSM21284 biofilms (magnification 1000X) after 24
hour treatment with 16X MIC of nisin A (Wt) and nisin I4V peptides.
doi:10.1371/journal.pone.0119684.g006
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While the mechanisms underlying the enhanced antimicrobial activity of lantibiotic vari-
ants have yet to be elucidated, the fact that lantibiotic properties can be improved is significant.
In the case of nisin A, it would appear that ring A is an exceptional target for bioengineering-
based approaches to generate more potent microbial inhibitors. Previous mutational studies
generated two ring A mutants [where ISL (Ile-Ser-Leu) at positions 4–6 were converted to KSI
(Lys-Ser-Ile) or KFI (Lys-Phe-Ile)] that were found to possess superior antimicrobial activity
against some non-pathogenic strains, in addition to showing an enhanced capacity to inhibit
the outgrowth of spores of Bacillus subtilis [32]. Interestingly, two natural nisin variants have
been reported that contain substituted residues at the position corresponding to isoleucine 4 in
nisin A. Nisin U, produced by strains of Streptococcus uberis, has 10 residue substitutions rela-
tive to nisin A which include a lysine at position 4 [49]. Recently, a novel nisin variant has been
described in which valine replaces isoleucine at position 4 (I4V) and alanine replaces leucine at
position 16 (L16A) [50]. Although it exhibits inhibitory activity against a range of staphylococ-
ci, Listeria and lactococci, the activity of this natural variant compared to its nisin A equivalent
has not been determined.
The opportunity also exists to combine nisin I4V with other antimicrobial agents, including
naturally derived compounds and currently utilized antibiotics, with a view to identifying syn-
ergistic anti-biofilm combinations. From a commercial perspective, it is notable that neither
Nisin A nor any other lantibiotic is currently employed commercially as a clinical antimicrobi-
al. Its potential with respect to clinical applications is strengthened by laboratory based experi-
ments highlighting its activity against human pathogens, including multi-drug resistant strains
[51,52]. Nisin could be applied in the form of a topical therapy as a treatment for generalized
bacterial skin infections, and/or used as an adjunct to systemic therapy. Indeed, combinations
of several topical antimicrobial preparations have been successful in the treatment of 6 out of
12 cutaneous MRSP infections [53]. Topical antimicrobial ingredients proven effective in cases
of pyoderma include chlorhexidine, benzoyl peroxide, ethyl lactate, mupirocin, fusidic acid and
nisin [54]. Alternatively, nisin could also be an effective inhibitor for biofilms which form on
in-dwelling devices or hospital equipment.
In conclusion, we have demonstrated the superior capacity of a bioengineered nisin
derivative to prevent biofilm formation as well as reduce the density of an established S. pseu-
dintermedius biofilm, which may have future applications as a stand-alone treatment or in
combination with antibiotics for the elimination of problematic biofilms and associated
infections.
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